Therapies aimed at preventing nuclear export of mutant SMARCB1 protein may represent a promising targeted therapy in ATRT harboring truncating C-terminal SMARCB1 mutations. Here, SMARCB1 is linked to atypical teratoid rhabdoid tumor.